| Trial ID: | L4443 |
| Source ID: | NCT00523913
|
| Associated Drug: |
Rosiglitazone
|
| Title: |
A Study Of BRL49653C For The Treatment Of Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: rosiglitazone
|
| Outcome Measures: |
Primary: The safety profile (adverse events, laboratory parameters and other observations) of BRL49653C administered for 52 weeks will be evaluated., 52 Weeks | Secondary: The efficacy profile (HbA1c, FPG and Insulin) of BRL49653C administered for 52 weeks will be evaluated., 52 Weeks
|
| Sponsor/Collaborators: |
Sponsor: GlaxoSmithKline
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
70
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2005-11
|
| Completion Date: |
2007-04
|
| Results First Posted: |
|
| Last Update Posted: |
2016-10-28
|
| Locations: |
GSK Investigational Site
|
| URL: |
https://clinicaltrials.gov/show/NCT00523913
|
